Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: Results from a multicentric European study

BJU International

Volumn 115, Issue 6, 2015, Pages 913-920

  Fossati, Nicola ^a   Lazzeri, Massimo ^b   Haese, Alexander ^c   McNicholas, Thomas ^d   De La Taille, Alexandre ^e   Buffi, Nicolò Maria ^b   Lughezzani, Giovanni ^b   Gadda, Giulio Maria ^a   Lista, Giuliana ^a   Larcher, Alessandro ^a   Abrate, Alberto ^a   Mistretta, Francesco ^a   Bini, Vittorio ^f   Redorta, Joan Palou ^g   Graefen, Markus ^c   Guazzoni, Giorgio ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d LISTER HOSPITAL   (United Kingdom)

^e Department of Digestive Surgery Mondor Hospital APHP   (France)

^f UNIVERSITY OF PERUGIA   (Italy)

^g FUNDACIÓ PUIGVERT   (Spain)

Author keywords

p2PSA; predictive models; prostate biopsy; prostate health index; PSA; young men

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ISOPROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER RISK; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT PARAMETERS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HEALTH INDEX; PROSTATE VOLUME; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; AGE; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; HEALTH STATUS INDICATOR; MIDDLE AGED; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

AGE FACTORS; CASE-CONTROL STUDIES; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; ROC CURVE;

EID: 84930047413     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12718     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 2013; 63: 11-30
2. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized european study. N Engl J Med 2009; 360: 1320-8
3. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
4. Heijnsdijk EAM, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605
5. Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 2013; 63: 693-701
6. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010; 341: c4521-1
7. AUA prostate cancer guidelines. 2013. Available at: https://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm. Accessed April 2013
8. Guazzoni G, Lazzeri M, Nava L, et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012; 61: 455-66
9. Guazzoni G, Nava L, Lazzeri M, et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-22
10. Lazzeri M, Haese A, la Taille de A, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric european study. Eur Urol 2013; 63: 986-94
11. Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS. BJU Int 2013; 112: 313-21
12. Lazzeri M, Lughezzani G, Larcher A, et al. Reply to Sergey Tadtayev, Thomas A. McNicholas, and Gregory B. Boustead's Letter to the Editor re: Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava et al. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol 2012;61:455-66. Eur Urol 2012; 62: e16-7
13. Semjonow A, Köpke T, Eltze E, Pepping-Schefers B, Bürgel H, Darte C,. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 2010; 43: 926-8
14. Epstein JI, Allsbrook WC, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42
15. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45
16. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-74
17. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012; 30: 3020-5
18. Moyer VA,. Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012; 157: 120-34
19. HelpAge International, Global AgeWatch Index. 2013: a summary. Available at: http://www.helpage.org/silo/files/global-agewatch-index-2013-a-summary.pdf. Accessed May 2014.
20. How to cope with an ageing population. Lancet 2013; 382: 1225
21. Loeb S, Roehl KA, Antenor JAV, Catalona WJ, Suarez BK, Nadler RB,. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67: 316-20
22. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364: 1708-17
23. Loeb S, Roehl KA, Helfand BT, Catalona WJ,. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 2008; 72: 887-91
24. Kim J, Ebertowski J, Janiga M, et al. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int 2013; 111: 934-40
25. Simardi LH, Tobias-MacHado M, Kappaz GT, Taschner Goldenstein P, Potts JM, Wroclawski ER,. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study. Urology 2004; 64: 1098-101
26. Hedelin H, Johansson N, Stroberg P,. Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol 2005; 39: 154-9
27. Lazzeri M, Briganti A, Scattoni V, et al. J Urol-PHI in positive repeated biopsy-Lazzeri. Juro 2012; 188: 1137-43
28. Rhodes T, Jacobson DJ, McGree ME, et al. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men. Juro 2012; 187: 92-6
29. Rhodes T, Jacobson DJ, McGree ME, et al. Longitudinal changes. Url 2012; 79: 655-61